| Literature DB >> 35409389 |
Alessio Danilo Inchingolo1, Giuseppina Malcangi1, Angelo Michele Inchingolo1, Fabio Piras1, Vito Settanni1, Grazia Garofoli1, Giulia Palmieri1, Sabino Ceci1, Assunta Patano1, Nicole De Leonardis1, Chiara Di Pede1, Valentina Montenegro1, Daniela Azzollini1, Maria Grazia Garibaldi1, Zamira Kruti1, Antonella Tarullo1, Giovanni Coloccia1, Antonio Mancini1, Biagio Rapone1, Alexandra Semjonova1, Denisa Hazballa1,2, Maria Teresa D'Oria1,3, Megan Jones1, Luigi Macchia4, Ioana Roxana Bordea5, Antonio Scarano6, Felice Lorusso6, Gianluca Martino Tartaglia7,8, Cinzia Maspero7,8, Massimo Del Fabbro7,9, Ludovica Nucci10, Kenan Ferati11, Arberesha Bexheti Ferati11, Nicola Brienza12, Alberto Corriero12, Francesco Inchingolo1, Gianna Dipalma1.
Abstract
Resveratrol is a polyphenol that has been shown to possess many applications in different fields of medicine. This systematic review has drawn attention to the axis between resveratrol and human microbiota, which plays a key role in maintaining an adequate immune response that can lead to different diseases when compromised. Resveratrol can also be an asset in new technologies, such as gene therapy. PubMed, Cochrane Library, Scopus, Web of Science, and Google Scholar were searched to find papers that matched our topic dating from 1 January 2017 up to 18 January 2022, with English-language restriction using the following Boolean keywords: ("resveratrol" AND "microbio*"). Eighteen studies were included as relevant papers matching the purpose of our investigation. Immune response, prevention of thrombotic complications, microbiota, gene therapy, and bone regeneration were retrieved as the main topics. The analyzed studies mostly involved resveratrol supplementation and its effects on human microbiota by trials in vitro, in vivo, and ex vivo. The beneficial activity of resveratrol is evident by analyzing the changes in the host's genetic expression and the gastrointestinal microbial community with its administration. The possibility of identifying individual microbial families may allow to tailor therapeutic plans with targeted polyphenolic diets when associated with microbial dysbiosis, such as inflammatory diseases of the gastrointestinal tract, degenerative diseases, tumors, obesity, diabetes, bone tissue regeneration, and metabolic syndrome.Entities:
Keywords: bone regeneration; dentistry; genic therapy; immune response; microbiome; microbiota; nutrition; resveratrol; resveratrol supplementation; thrombosis
Mesh:
Substances:
Year: 2022 PMID: 35409389 PMCID: PMC8999966 DOI: 10.3390/ijms23074027
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Summary of the RSV metabolites and the main molecules indicated for their antioxidant and anti-inflammatory bioactivity.
Figure 2Summary of the cytokines’ and mediators’ modulation correlated to the anti-inflammatory properties of RSV. The RSV is able to interact with the SIRT-1 pathway in order to inhibit the pro-inflammatory mediators’ cascade and the COX-1 and COX-2.
Figure 3Summary of the pathway correlated to the bacteria infection protective properties of RSV. RSV pathways are able to produce a signals cascade involving Sirtuin 1 [SIRT-1], adenosine monophosphate (AMP)-activated protein Kinase [AMPK] (blue arrow), liver-kinase B1 [LKB1] (grey arrow), and peroxisome proliferator-activated receptor-γ coactivator [PGC-1α].
Database search indicators. No publication period limitations have been considered.
|
|
Figure 4PRISMA flowchart diagram of the inclusion process [131].
Reported RSV results in obese individuals with metabolic syndrome.
| Ref. | Authors (Year) | Type of the Study/Days | Aim of the Study | Materials | Results |
|---|---|---|---|---|---|
| [ | Walker et.al | A pilot randomized placebo-controlled clinical trial |
If high dose RSV improve insulin sensitivity and glucose tolerance in obese men suffering insulin resistance and the MS If RSV induced changes in the MS do they bring about changes in gut GM and on gene expression of adipose tissue | 28 obese men with MS − BMI > 30–40 kg/m2 − Insulin resistance M ≤ 6.5 mg/kg/min − Age 30–70 years − Mix Caucasians and non-Caucasians | No significant effect on insulin sensitivity or glucose homeostasis but during a 2-h oral GTT, post hoc analysis was seen a significant improvement in insulin sensitivity and glucose tolerance in Caucasian subject |
| [ | Korsholm et.al | A randomized | A comprehensive metabolomic analysis of the changes caused in middle-aged men with MS by RSV | 66 obese men with MS − BMI > 30 kg/m2 − Age 30–60 years − Metabolomic analysis on blood, urine, adipose tissue, and skeletal muscle tissue | RSV supplementation reduces sulfated androgen precursors, at the same time lipid metabolism was affected and urinary derivates of aromatic amino acids reflect the composition of gut microbiota. |
| [ | Most et.al | A randomized | To evaluate the effect of combined EGCG–RSV supplementation on gut microbiota composition. | 42 obese men and women − BMI > 25 kg/m2 − Age 20–50 years − Caucasian men and women | EGCG–RSV supplementation reduced Bacteroidetes and tended to reduce Fecalibacterium in men. The composition of men’s baseline microbiota determined the increase in fat oxidation after EGCG–RSV supplementation. |
Effects of RSV and phenolic compounds on glucose uptake and metabolism in muscle cells, Lactobacillus adherence to intestinal epithelial cells, and S.Mutans cariogenic activity.
| Ref. | Authors (Year) | Type of the Study/Days | Aim of the Study | Materials | Results |
|---|---|---|---|---|---|
| [ | Houghton et al. (2019) | Research in vitro | Investigate the impact of microbiota-derived phenolic metabolites on glucose uptake and metabolism in muscle cells in myotubes treated with insulin and glucose | LHCN-M2 myoblasts | Many of the compounds tested increased glucose absorption and metabolism, but most notablyisovanillic acid 3-O-sulfate (IVAS) by a dose-dependent mechanism through the GLUT 4 transporter and PI3K pathway |
| [ | Jarosova et al. | Research in vitro | RSV increases bacterial | Bacterial strains: | No statistically significant result on the adhesion of any strain |
| [ | Li et al. | Research in vitro | Evaluate anticariogenic activity of RSV on | Bacterial strain | RSV reduced the synthesis of water-soluble and water-insoluble polysaccharides and lowered acid production and tolerance at sub-MIC doses, compromising biofilm formation. Virulence factors were inhibited as concentrations of RSV increased |
Reported RSV results in the colonic environment and GM.
| Ref. | Authors (Year) | Type of the Study/Days | Aim of the Study | Materials | Results |
|---|---|---|---|---|---|
| [ | Jarosova et al. | In vitro study 48 h study | To analyze the effectiveness of selected stilbenoids (batatasin III, oxyRSV, piceatannol, pinostilbene, RSV, thunalbene) in the colon | In vitro fecal fermentation system | The stilbenoids vary their stability in a colonic environment. |
| [ | Jaimes et.al | In vitro study of fecal bacteria of 4 volunteer donors | To explore the effect of six stilbenoids (batatasin III, oxyRSV, piceatannol, pinostilbene, RSV, thunalbene) on the gut microbiota composition. | Fecal fermentation (FFM) system | The tested stilbenoidsmodulate the GM |
| [ | Heng et.al | In vitro study to identify the TMA inhibitors | To identify choline-degrading bacteria from healthy human feces and used for screening of trimethylamine (TMA)-lyase inhibitors | Stool samples from healthy adult college students | The treatment with β-sitosterol and RSV |
Included studies that focus on the immune-system–microbiota–resveratrol axis.
| Ref. | Authors (Year) | Type of the Study/Days | Aim of the Study | Materials | Results |
|---|---|---|---|---|---|
| [ | Liu et al. (2020) | Clinical trial | RSV exhibits antibacterial effects against | Human antimicrobial peptides | RSV exhibits antibacterial effect |
| [ | Zainal et al. (2017) | Randomized controlled trial | RSV in | RSV | RSV suppresses DENV replication |
| [ | Yang et al. (2021) | Randomized controlled trial | RSV attenuates | Different doses of RSV (5, 10, 25, and 50 μM | RSV inhibited |
| [ | Hwang e Lim (2019) | Research letter | RSV controls | AcrAB-TolC multidrug efflux pump in | RSV gives inhibition of the AcrAB-TolC pump in |
| [ | Baldassarre et al. (2020) | Randomized double-blind trial | RSV with CM-glucan in infants with common cold | Solution containing RSV plus carboxymethyl-β-glucan | RSV and CM-glucan can alleviate nasal |
Reported RSV results in bone regeneration.
| Ref. | Authors (Year) | Type of the Study/Days | Aim of the Study | Materials | Results |
|---|---|---|---|---|---|
| [ | Zhang et.al | Research in vitro |
If RSV with or without SrRn has differentiating power on the MSC; If RSV with or without SrRn inhibits the action of osteoclasts; If RSV with or without SrRn induces angiogenesis If in rats rehabilitated with 3D scaffolds with RSV associated or not with SrRn, there is bone formation |
− Scaffold only − Scaffold with SrRn − Scaffold with RSV − Scaffold with RSV and SrRn |
MSC proliferation in scaffolds with SrRn is greater than other groups; Action of osteoclasts is inhibited in scaffolds with RSV, SrRn and both; Angiogenic effect is greatest in scaffolds with RSV; High bone formation in mandible with scaffolds with RVS and SrRn compared to the other two groups. |
| [ | Borsani et.al | Research in vitro | The researchers wanted to see how CGFs and/or resveratrol affected the proliferation and differentiation of human osteoblasts, whether they were treated with bisphosphonates or not. | Osteoblast growth medium (OGM): control group |
CGF and RSV both have an osteogenic impact and protect ZOL-treated osteoblasts; In osteoblasts treated with RSV + ZOL or CGF + RSV + ZOL, OPG levels are higher; BMP-2 levels rose sharply in osteoblasts treated with CGF + RSV + AL or CGF + RSV + ZOL, but not as much as in osteoblasts treated with CGF + ZOL; There is a rise in SIRT-1 and Col 1 in osteoblastic cells treated with RSV + CGF + ZOL; Human osteoblastic cells treated with RSV deposited substantial amounts of calcium. |